Identification of SPP1 + macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics
2024

Identifying Immune Suppressor Macrophages in Liver Cancer

Sample size: 421 publication 10 minutes Evidence: high

Author Information

Author(s): Jin Han, Kim Woonghee, Yuan Meng, Li Xiangyu, Yang Hong, Li Mengzhen, Shi Mengnan, Turkez Hasan, Uhlen Mathias, Zhang Cheng, Mardinoglu Adil

Primary Institution: Central Laboratory, Tianjin Medical University General Hospital, Tianjin, China; Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm, Sweden; Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Türkiye; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, United Kingdom

Hypothesis

SPP1 + macrophages play a critical role in immunosuppression in hepatocellular carcinoma.

Conclusion

SPP1 + macrophages are identified as unfavorable immune suppressors in hepatocellular carcinoma, while other macrophage types and CD8 + T cells are associated with better patient outcomes.

Supporting Evidence

  • SPP1 + macrophages were found to inhibit CD8 + T cell proliferation.
  • High levels of SPP1 + macrophages correlated with poor patient outcomes.
  • Integrative analysis revealed distinct roles of different macrophage types in HCC.
  • SPP1 inhibition in macrophages shifted their phenotype towards a more favorable type.
  • Survival analysis indicated that high proportions of CD8 + T cells are associated with better prognosis.
  • Single-cell RNA-seq data showed that SPP1 + macrophages interact with T cells through the SPP1 – CD44 axis.
  • SPP1 expression was inversely correlated with CD8 + T cell infiltration.
  • Targeting SPP1 may enhance the effectiveness of immunotherapy in HCC.

Takeaway

Some special immune cells in liver cancer can stop other immune cells from working, which is not good for patients. Finding ways to change these cells could help treat the cancer better.

Methodology

The study analyzed bulk RNA-seq data from two cohorts and integrated it with single-cell RNA-seq data to assess immune cell types and their impact on patient survival.

Potential Biases

Potential biases may arise from the limited sample size of the scRNA-seq cohort.

Limitations

The scRNA-seq discovery cohort included samples from a limited number of patients, which may not fully represent macrophage subpopulations.

Participant Demographics

Patients with hepatocellular carcinoma from two independent cohorts.

Statistical Information

P-Value

1.22E-33

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1446453

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication